Dr. McGregor is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Boston, MA 02215Phone+1 617-632-6328
Summary
- Dr. Bradley McGregor is an oncologist in Boston, MA and is affiliated with Dana-Farber Cancer Institute. He received his medical degree from Tufts University School of Medicine and has been in practice 13 years. He specializes in genitourinary oncology and hematologic oncology.
Education & Training
San Antonio Uniformed Services Health Education ConsortiumFellowship, Hematology and Medical Oncology, 2007 - 2010- San Antonio Uniformed Services Health Education ConsortiumResidency, Internal Medicine, 2004 - 2007
Tufts University School of MedicineClass of 2004
Certifications & Licensure
CA State Medical License 2012 - Present
FL State Medical License 2022 - Present
ME State Medical License 2022 - 2026
OH State Medical License 2022 - 2026
RI State Medical License 2022 - 2026
VT State Medical License 2022 - 2026
CT State Medical License 2022 - 2025
American Board of Internal Medicine Medical Oncology- Join now to see all
Clinical Trials
- Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Start of enrollment: 2017 Dec 28
- Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression Start of enrollment: 2019 Nov 27
Publications & Presentations
PubMed
- COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts.Sumanta K Pal, Yohann Loriot, Andrea Necchi, Parminder Singh, Daniel Castellano
Journal of Clinical Oncology. 2025-02-18 - A neoantigen vaccine generates antitumour immunity in renal cell carcinoma.David A Braun, Giorgia Moranzoni, Vipheaviny Chea, Bradley A McGregor, Eryn Blass
Nature. 2025-02-05 - A Call for a Neoadjuvant Kidney Cancer Consortium: Lessons Learned from Other Cancer Types.Axel Bex, Michael Jewett, Bryan Lewis, E Jason Abel, Laurence Albiges
European Urology. 2025-01-23
Journal Articles
- Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell CarcinomaPraful Ravi, Charlene Mantia, Christopher Su, Neeraj Agarwal, Yousef Zakharia, Rana R Mckay, Vivek Narayan, Ajjai Alva, Bradley A Mcgregor, David F Mcdermott, Toni K C..., JAMA Oncology
Authored Content
- Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell CarcinomaMay 2020
- Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell CarcinomaMay 2020
Press Mentions
“Unprecedented” Data Reinforce First-Line Enfortumab Vedotin Combo for Advanced Bladder CancerFebruary 19th, 2025- ADC Advances, Potential Practice-Changing Research on Tap for ASCO GU 2025February 10th, 2025
- Trial Finds No Benefit of Adding Nivolumab to Tivozanib for Advanced Kidney CancerSeptember 14th, 2024
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
